Skip to main content
. 2015 Aug 24;16(8):20033–20049. doi: 10.3390/ijms160820033

Figure 5.

Figure 5

Calreticulin (CRT) exposure detected by immunofluoroscence assay after treatment of X12-PG. (AD) were respectively treated with 0, 400, 800, 1600 μg/mL X12-PG for 48 h, then incubated with primary antibody (Anti-Calreticulin, diluted 1:200 in blocking buffer) and detected with the FITC-labeled secondary antibody. Fluorescence intensity was visualized by immunofluorescence microscopy (×200).